Replimune Group (REPL) Launches TUDRIQEV On Early Uptake With Valuation Still In Focus
Replimune Group stock reacts to TUDRIQEV launch and earnings update
Replimune Group (REPL) is in focus after the commercial launch of TUDRIQEV for advanced melanoma, paired with quarterly results that showed a narrower loss and ongoing investment in its cancer portfolio.
The recent move in Replimune Group’s share price has been sharp, with an 8.28% 1 day share price return capping a 45.04% 7 day and 55.27% 90 day share price return, while total shareholder return over five years is still down 47.82%. This shows strong short term momentum alongside a weaker long term record.
Scan beyond Replimune Group and see how other oncology and healthcare specialists with recent traction line up in the 36 healthcare AI stocks.
After a near 1x gain year to date and strong momentum around TUDRIQEV, the debate now shifts. Is most of the easy upside already in the rear-view mirror, or does Replimune Group still trade at a discount to its potential?
Most Popular Narrative: 11% Undervalued
Replimune Group closed at $17.39, while the most followed narrative pegs fair value at $19.50. The current quote sits below that implied level and puts the focus squarely on TUDRIQEV execution and the broader RPx pipeline.
The FDA accelerated approval of TUDRIQEV in combination with nivolumab for unresectable advanced cutaneous melanoma that progressed on a PD-1 regimen opens access to an estimated 10,000 US patients each year and creates a new revenue stream that is not yet fully reflected in Replimune Group’s reported earnings.
The planned commercial rollout starts with roughly 200 high-volume early adopter hospital accounts, supported by an operational excellence team and a next-day drop ship delivery model. This strategy is aimed at driving faster product uptake and could lift revenue growth and operating leverage as fixed commercial costs are spread over more units.
See why 1 investors see Replimune Group as 11% undervalued.
Result: Fair Value of $19.50 (UNDERVALUED)
Still, the TUDRIQEV story hinges on confirming survival benefit and on physicians accepting a roughly US$450,000 treatment price, where slower uptake could blunt the bullish narrative.
Find out about the key risks to this Replimune Group narrative.
Next Steps
If this mix of optimism and caution around Replimune Group feels familiar, do not sit on the fence. Review both sides of the story and weigh the 2 key rewards and 5 important warning signs.
Looking for more Replimune Group style investment ideas?
You have already done the work on Replimune Group, so keep that momentum going and line up your next potential opportunity before the market moves first.
- Target resilient cash generators with fortress style balance sheets by scanning the list of solid balance sheet and fundamentals (23 results) and filtering for businesses that match your risk tolerance.
- Hunt for quality at a reasonable entry point by running the 30 high quality undervalued stocks and spotting companies where fundamentals do not match current pricing.
- Lock in potential income ideas by reviewing the 7 dividend fortresses and focusing on businesses offering higher yields backed by solid underlying metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com